Cassava Sciences

Cassava Sciences is a clinical-stage biopharmaceutic company that develops novel therapeutics for the treatment of Alzheimer’s disease. Read more

76 Followers on Owler
76 Followers on Owler
76 Followers on Owler
76 Followers on Owler

Cassava Sciences

Cassava Sciences is a clinical-stage biopharmaceutic company that develops novel therapeutics for the treatment of Alzheimer’s disease. Read more

Remi Barbier's photo - President & CEO of Cassava Sciences

President & CEO

Remi Barbier

CEO Approval Rating

84/100

Founded:

1998

Status:

PublicIndependent CompanyNASDAQSAVA

CASSAVA SCIENCES TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Cortexyme is Cassava Sciences's top competitor. Cortexyme is a Public company that was founded in South San Francisco, California in 2012. Cortexyme operates in the Biotechnology industry. Cortexyme has 28 more employees vs. Cassava Sciences.

Alzheon has been one of Cassava Sciences's top competitors. Alzheon is headquartered in Framingham, Massachusetts, and was founded in 2013. Alzheon is in the Biotechnology field. Alzheon generates ∞% the revenue of Cassava Sciences.

Cerecin is perceived as one of Cassava Sciences's biggest rivals. Cerecin was founded in 2001 in Tanjong Pagar, Other. Cerecin competes in the Pharmaceuticals field. Cerecin generates $7M more revenue than Cassava Sciences.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Travecta a competitor of Cassava Sciences?

Cassava Sciences Quarterly and Annual Revenue

Coming soon for Cassava Sciences!

Annual Revenue

Cassava Sciences Acquisitions

No recent acquisitions found related to Cassava Sciences

Cassava Sciences Funding History

Since Cassava Sciences was founded in 1998, it has participated in 1 round of funding. In total Cassava Sciences has raised $200.0M. Cassava Sciences' funding round was on Feb 2021 for a total of $200.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Private Placement
Feb 2021
$200M
-

Since Cassava Sciences was founded in 1998, it has participated in 1 round of funding. In total Cassava Sciences has raised $200.0M. Cassava Sciences' funding round was on Feb 2021 for a total of $200.0M

Cassava Sciences Investments

No recent investments found related to Cassava Sciences

Cassava Sciences News

March 10, 2021Zacks

Here's Why

Cassava Sciences (SAVA) is progressing well with development of its Alzheimer's disease candidate, si... See more »
February 23, 2021Zacks

What's in Store?

Cassava Sciences (SAVA) will provide updates on its pipelinewhen it reports fourth-quarter 2020 resul... See more »
February 22, 2021Business Insider

Cassava Sciences jumps 16% on meeting with FDA paving the way for phase 3 study of Alzheimer's treatment

The biotech company is on track to move forward with a pivotal phase-three study for Simufilam, its l... See more »
February 22, 2021Benzinga

Cassava Sciences To Start Two Pivotal Trials With Simufilam In Alzheimer's

Cassava Sciences Inc (NASDAQ: SAVA) completes an End-of-Phase 2 (EOP2) meeting with the FDA for its l... See more »

Cassava Sciences Press Releases

August 24, 2020GlobeNewswire

Cassava Sciences Announces Lead Drug Candidate PTI-125 Is Assigned the Chemical Drug Name 'sumifilam' by USAN

- Sumifilam Is First of a New Class of Drugs That Target Filamin Proteins -... See more »
July 9, 2020GlobeNewswire

Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference

AUSTIN, Texas, July 09, 2020 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq:SAVA), a biotechnolog... See more »
May 15, 2020LD Micro

Top-line Results from a Phase 2b Study of PTI-125 in Alzheimer's Disease Does Not Meet Primary Endpoint

Read this press release and other recent news about Cassava Sciences Inc. (SAVA) at ldmicro.com... See more »
January 28, 2020GlobeNewswire

Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer's Disease

Top-Line Results Expected Mid-year 2020Top-Line Results Expected Mid-year 2020... See more »
December 6, 2019StreetInsider

Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer's Disease at CTAD 2019

- New Data Shows Clinical Evidence of Target Engagement and Target Validation - Company Expects Data ... See more »
April 11, 2019PRcom

Exclusive Speaker Interviews with AstraZeneca, Ensysce Biosciences & Metys Pharmaceuticals Released for Pain Therapeutics 2019

SMi reports: Metys Pharmaceuticals, Ensysce Biosciences & AstraZeneca will be speaking and presenting... See more »
January 17, 2019GlobeNewswire

Pain Therapeutics Announces Academic Collaboration with The University of Texas at Austin

AUSTIN, Texas, Jan. 17, 2019 (GLOBE NEWSWIRE) -- Pain Therapeutics, Inc. (Nasdaq: PTIE), a drug devel... See more »

Social Media

Cassava Sciences Headquarters

7801 N. Capital of Texas Highway Suite 260

Austin, Texas78731

512-501-2444

Driving Directions »

Trending Companies

Cassava Sciences Summary

ABOUT

Overview

Cassava Sciences is a clinical-stage biopharmaceutic company that develops novel therapeutics for the treatment of Alzheimer’s disease. Cassava Sciences was founded in 1998. Cassava Sciences' headquarters is located in Austin, Texas, USA 78731. It ha...

CEO

Cassava Sciences's President & CEO, Remi Barbier, currently has an approval rating of 84%. Cassava Sciences's primary competitors are Cortexyme, Alzheon & Cerecin.

Website

cassavasciences.com

Frequently Asked Questions about Cassava Sciences

  1. When was Cassava Sciences founded?

    Cassava Sciences was founded in 1998
  2. Who is Cassava Sciences's CEO?

    Cassava Sciences's CEO is Remi Barbier
  3. How much revenue does Cassava Sciences generate?

    Cassava Sciences generates $ < 1M in revenue
  4. How much funding does Cassava Sciences have?

    Cassava Sciences has historically raised $200M in funding
  1. Where is Cassava Sciences's headquarters?

    Cassava Sciences's headquarters is in Austin Texas, USA
  2. How many employees does Cassava Sciences have?

    Cassava Sciences has 9 employees
  3. What sector does Cassava Sciences operate in?

    Cassava Sciences is in Biotechnology, Pharmaceuticals
  4. Who are Cassava Sciences's competitors?

    Cassava Sciences's top competitors are Cortexyme, Alzheon, Cerecin